Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
12.08
-0.03 (-0.25%)
Jan 21, 2026, 1:58 PM EST - Market open
DAWN Employees
Day One Biopharmaceuticals had 181 employees as of December 31, 2024. The number of employees increased by 26 or 16.77% compared to the previous year.
Employees
181
Change (1Y)
26
Growth (1Y)
16.77%
Revenue / Employee
$738,519
Profits / Employee
-$838,442
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 181 | 26 | 16.77% |
| Dec 31, 2023 | 155 | 34 | 28.10% |
| Dec 31, 2022 | 121 | 66 | 120.00% |
| Dec 31, 2021 | 55 | 35 | 175.00% |
| Dec 31, 2020 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DAWN News
- 8 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - GlobeNewsWire
- 15 days ago - Day One Completes Acquisition of Mersana Therapeutics - GlobeNewsWire
- 4 weeks ago - Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish - Seeking Alpha
- 5 weeks ago - Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting - GlobeNewsWire
- 2 months ago - Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout - Benzinga